PedAM
Pediatric Disease Annotations & Medicines
| Disease | obstructive sleep apnea |
| Symptom | C0917799|excessive sleepiness |
| Sentences | 11 |
| PubMedID- 22640618 | Modafinil is a wake-promoting drug used for the treatment of excessive daytime sleepiness due to narcolepsy as well as excessive sleepiness associated with obstructive sleep apnea and shift work disorder. |
| PubMedID- 21118743 | Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. |
| PubMedID- 20957845 | Study objectives: this 12-month, open-label, flexible-dose study with an extension period evaluated the tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea (osa), shift work disorder (swd), or narcolepsy. |
| PubMedID- 20307223 | Armodafinil is a wake-promoting agent approved in 2007 by the us food and drug administration for the treatment of excessive sleepiness arising from narcolepsy, obstructive sleep apnea (osa; even after optimal treatment for the underlying obstruction) and shift-work disorder (swd). |
| PubMedID- 25558302 | Healthcare costs among patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy. |
| PubMedID- 23891038 | The cholinergic system may play a role in the pathophysiology of residual excessive sleepiness in patients with obstructive sleep apnea. |
| PubMedID- 22803602 | Armodafinil , the r-enantiomer of modafinil, approved for treating excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder, is possibly effective as an adjunctive treatment for bipolar depression. |
| PubMedID- 20957846 | Its efficacy and tolerability have been established in 12-week studies of patients with excessive sleepiness (es) associated with treated obstructive sleep apnea (osa), shift work disorder (swd), or narcolepsy. |
| PubMedID- 24897888 | Prevalence and correlates of insomnia and excessive sleepiness in adults with obstructive sleep apnea symptoms. |
| PubMedID- 24532997 | Study registration: double-blind, placebo-controlled, functional neuroimaging study of armodafinil (200 mg/day) on prefrontal cortical activation in patients with residual excessive sleepiness associated with obstructive sleep apnea/hypopnea. |
| PubMedID- 20051221 | A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression. |
Page: 1